Publications by authors named "T Systchenko"
France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.
View Article and Find Full Text PDFArticle Synopsis
- F-FDG PET/CT is important for diagnosing and monitoring Hairy Cell Leukemia (HCL), especially in atypical cases with bone involvement.
- The study highlighted two patients with BRAF mutation who had significant bone lesions and limited bone marrow infiltration, demonstrating the utility of F-FDG PET/CT.
- The authors emphasize integrating F-FDG PET/CT into standard HCL management to improve patient outcomes and detect less common manifestations.
Article Synopsis
- Myeloproliferative neoplasms in the blastic phase (MPN-BP) have a poor prognosis, but a study on five patients showed promising results with a new treatment combining azacytidine, venetoclax, and ruxolitinib.* -
- The patients, aged between 72 and 84, had an overall response rate of 80%, with 40% achieving complete remission during a median follow-up of 10 months.* -
- There were no unexpected toxicities from the treatment, and the patients experienced an improved quality of life, with a median overall survival of 13.4 months.*
Article Synopsis
- Preservation of fertility is increasingly important for young women with Hodgkin lymphoma (HL), prompting a study on the effects of the ABVD chemotherapy regimen on their reproductive health.
- The study involved 67 female patients of childbearing age, revealing that about 53.7% became pregnant after treatment, which is similar to the 54.5% pregnancy rate in controls not exposed to chemotherapy.
- Results indicated no significant differences in pregnancy rates, birth outcomes, or time to pregnancy between patients treated with ABVD and the control group, suggesting that females with HL can be reassured about their fertility post-treatment.
Novel treatments are needed to address the lack of options for patients with relapsed or refractory multiple myeloma. Even though immunotherapy-based treatments have revolutionized the field in recent years, offering new opportunities for patients, there is still no curative therapy. Thus, non-immunologic agents, which have proven effective for decades, are still central to the treatment of multiple myeloma, especially for advanced disease.
View Article and Find Full Text PDF